Mast cell neoplasia in dogs

Veterinary Medicine

Volumn 96, Issue 12, 2001, Pages 919-928

  Fan, Timothy M ^c   Kitchell, Barbara E ^c   Daliwahl, Ravinder S ^a,b  

^a Veterinary Teaching Hospital   (United States)

^b All Care Animal Referral Center   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0041083261     PISSN: 87507943     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Brodey, R.S.: Canine and feline neoplasia. Adv. Vet. Sci. Comp. Med. 14:309-354; 1970.
2. Patnaik, A.K. et al.: Canine cutaneous mast cell tumor: Morphologic grading and survival time in 83 dogs. Vet. Pathol. 21 (5):469-474; 1984.
3. Miller, D.M.: The occurrence of mast cell tumors in young Shar-Peis. J. Vet. Diagn. Invest. 7 (3):360-363; 1995.
4. Cohen, D. et al.: Epidemiological analysis of the most prevalent sites and types of canine neoplasia observed in a veterinary hospital. Cancer Res. 34 (11):2859-2868; 1974.
5. Macy, D.W.: Canine and feline mast cell tumors: Biologic behavior, diagnosis, and therapy. Semin. Vet. Med. Surg. (Small Anim.) 1 (1):72-83; 1986.
6. Hottendorf, G.H.; Nielsen, S.W.: Pathologic report of 29 necropsies on dogs with mastocytoma. Pathol. Vet. 5 (2):102-121; 1968.
7. O'Keefe, D.A. et al.: Systemic mastocytosis in 16 dogs. J. Vet. Intern. Med. 1 (2):75-80; 1987.
8. Vail, D.M.: Mast cell tumors. Small Animal Clinical Oncology, 2nd Ed. (S.J. Withrow; E.G. MacEwen, eds.). W.B. Saunders, Philadelphia, Pa., 1996; pp 192-210.
9. Bookbinder, P.F. et al.: Determination of the number of mast cells in lymph node, bone marrow, and buffy coat cytologic specimens from dogs. JAVMA 200 (11):1648-1650; 1992.
10. McManus, P.M.: Frequency and severity of mastocytemia in dogs with and without mast cell tumors: 120 cases (1995-1997). JAVMA 215 (3):355-357; 1999.
11. Leibman, N.F. et al.: Cytologic comparison of mast cell numbers in liver and spleen of normal dogs and dogs with mast cell tumors. Proc. 19th Annual Veterinary Cancer Society Conference, Wood's Hole, Mass., 1999; p 28.
12. Siegel, S. et al.: Evaluation of a staging protocol for cutaneous mast cell tumors. Proc. 2nd Annual Mid-Year Conference of the Veterinary Cancer Society, Tucson, Ariz., 2000; p 22.
13. Hahn, K.A. et al.: The usefulness of hepatic and splenic fine needle aspiration cytology in the clinical staging of canine cutaneous mast cell tumors. An evaluation of 88 dogs. Proc. 2nd Annual Mid-Year Conference of the Veterinary Cancer Society, Tucson, Ariz., 2000; p 23.
14. Mayr, B. et al.: Cytogenetic, ras, and p53: Studies in cases of canine neoplasms (hemangiopericytoma, mastocytoma, histiocytoma, chloroma). J. Hered. 90 (1):124-128; 1999.
15. Gamblin, R.M. et al.: Overexpression of p53 tumor suppressor protein in spontaneously arising neoplasms of dogs. AJVR 58 (8):857-863; 1997.
16. Ginn, P.E. et al.: Immunohistochemical detection of p53 tumor-suppressor protein is a poor indicator of prognosis for canine cutaneous mast cell tumors. Vet. Pathol. 37 (1):33-39; 2000.
17. Jaffe, M.H. et al.: Immunohistochemical and clinical evaluation of p53 in canine cutaneous mast cell tumors. Vet. Pathol. 37 (1):40-46; 2000.
18. Leibman, N. et al.: Identification of matrix metalloproteinases in canine mast cell tumors. Proc. 18th Annual Veterinary Cancer Society Conference, Estes Park, Colo., 1998; p 16.
19. Tsujimura, T. et al.: Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 83 (9):2619-2626; 1994.
20. Kanakura, Y. et al.: Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 8 (suppl. 1):S18-S22; 1994.
21. London, C.A. et al.: Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp. Hematol. 27 (4):689-697; 1999.
22. Ma, Y. et al.: Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. J. Invest. Dermatol. 112 (2):165-170; 1999.
23. Zerbe, D. et al.: Analysis of c-kit juxtamembrane domain duplications in canine mast cell tumors. Proc. 2nd Annual Mid-Year Conference of the Veterinary Cancer Society, Tucson, Ariz., 2000; p 9.
24. Ma, Y. et al.: Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells. J. Invest. Dermatol. 114 (2):392-394; 2000.